Abstract: There is provided an acid addition salt of (?)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (?)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (?)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.

Abstract: The present invention relates to a method of treating various neurodegenerative disorders, in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.

Abstract: The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.

Abstract: There is provided an acid addition salt of (?)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (?)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (?)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.

Abstract: [wherein n represents an integer of from 1 to 4, R1 represents substituted or unsubstituted lower alkyl, —C(?Y)R9 or the like, R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like, R3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group or the like, and R4 represents halogen or the like.]A phosphodiesterase 10A inhibitor which comprises a quinoline derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is provided.

Abstract: An object of the present invention is to provide a novel medicament with which motor neuron diseases can be treated. According to the present invention, there is provided a therapeutic agent for motor neuron diseases which comprises 3-methyl-1-phenyl-2-pirazoline-5-on or physiologically acceptable salts thereof as an active ingredient.

Abstract: The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): 1

Abstract: A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and/or abacterial prostatitis.

Abstract: The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof as an active ingredient wherein X1, X2, R1, R2, R3 and R4 are herein defined.

Abstract: The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): 1

Abstract: Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. The compound has an antagonistic effect on muscarinic M3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.

Abstract: Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same. ##STR1## The compound has an antagonistic effect on muscarinic M.sub.3 receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.

Abstract: The present invention relates to an novel anti-motoneuron-disease agent, comprising superoxide dismutase conjugated with lecithin through chemical crosslinking represented in the following generic formula (PC-SOD) as an effective ingredient:SOD--?C(O)--(CH.sub.2).sub.n --C(O)--X!.sub.mwherein SOD represents superoxide dismutase and X represents a residue of lysolecithin having a hydroxy group at position 2 of glycerol whose hydrogen atom of the hydroxyl group at position 2 is removed.A pharmaceutical agent of the present invention may improve symptoms of motoneuron diseases such as amyotrophic lateral sclerosis etc. by oral or parenteral administration. The present invention also relates to a novel treatment method for motoneuron disease by administrating PC-SOD and novel use of PC-SOD as a medical composition for preparing an agent for treating motoneuron disease.

Abstract: A clock signal generator produces a basic clock signal. A variable delay device is operative for delaying the basic clock signal by an adjustable interval and thereby converting the basic clock signal into a delay-resultant clock signal. A pseudo-noise code is generated at a timing depending on the delay-resultant clock signal. A spread-spectrum information signal is despread into a non-spread information signal in response to the pseudo-noise code. A correlator detects a correlation between the spread-spectrum information signal and the pseudo-noise code. The adjustable interval provided by the variable delay device is controlled in response to the detected correlation to provide synchronization between the spread-spectrum information signal and the pseudo-noise code.

Abstract: A wireless data communication system comprises: base stations located to have cells arranged equidistantly therebetween; mobile units, each being located within either of the cells, each of the base stations communicating with mobile units within its cell through plural channels provided by FDM. In the system, each of the base station may comprise a detector for monitoring the channels and detecting a free channel, and a transmission portion for continuously transmitting a signal including data indicative of the detected free channel. In the system, the plurality of channels used in one of cells have given frequency bands respectively which are the same as given frequency bands in other cells. In the system, each of the mobile stations may comprise a chip synchronizing circuit for effecting chip synchronizing between the each of the mobile stations and its base station.

Abstract: In a position measuring system, a position of a moving body is derived when data is sufficient for such derivation. On the other hand, when data is insufficient for such derivation, an area which may include the position of the moving body is derived. Accordingly, a user correctly evaluates reliability of information which is displayed. In a position measuring method, a measurement error of the derived position is evaluated. Further, a moving error evaluation is performed to evaluate an increase of the error. By changing the measurement error of the derived position, the area which includes the position of the moving body with high reliability can be displayed to the user.

Abstract: The present invention relates to pyrimidine compounds represented by the formula ##STR1## (wherein X is a substituted or a cyclic amino group and Y is a substituted amino group or a substituted carbonyl group) or their pharmaceutically acceptable salts, and a therapeutic agent for neurological diseases comprising the compounds.These compounds are useful for treatment of various disorders in nervous systems since they are effective on growth of neurons and promotion of the formation and elongation of neutrites.

Abstract: A method, for use in a receiver for the NAVSTAR global positioning system (GPS), of deriving successive values of phase of a received pseudo-random code signal following a momentary interruption of satellite signal reception, with the effects of signal noise eliminated by averaging processing, by first setting a replica pseudo-random code signal to an initial phase value which provides high correlation with the received code signal, and thereafter periodically executing phase derivation operations to obtain the phase of the received code signal, by obtaining the phase difference between the received and replica code signals, obtaining the average value of all of such phase differences obtained up to that point since the initial phase derivation operation, and adding that average value to the sum of a phase value obtained in the first phase derivation operation and a total estimated amount of change of phase of the received code since that first operation.

Abstract: A GPS receiver comprising a pseudonoise generator for simultaneously generating pseudonoise signals respectively corresponding to satellite electromagnetic waves transmitted from two or more satellites, an oscillator for simultaneously regenerating carrier waves of the plurality of satellite electromagnetic waves, and a plurality of demodulators responsive to the regenerated carrier waves and the pseudonoise signals to demodulate individual satellite electromagnetic waves independently, to thereby regenerate data transmitted from individual satellites, each demodulator being operative, during demodulation, to detect a set of phases of one pseudonoise signal and one regenerated carrier wave relative to one satellite electromagnetic wave on time division basis and including a first mixer for mixing of one pseudonoise signal, a second mixer for mixing of one regenerated carrier wave and a filter, whereby a set of phases of one pseudonoise signal and one regenerated carrier wave is changed to another set at timed